Pure Global

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer - Trial NCT06048705

Access comprehensive clinical trial information for NCT06048705 through Pure Global AI's free database. This Phase 1 trial is sponsored by GlaxoSmithKline and is currently Terminated. The study focuses on Neoplasms. Target enrollment is 7 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06048705
Phase 1
Terminated
drug
Trial Details
ClinicalTrials.gov โ€ข NCT06048705
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Assessment of Safety and Recommended Phase 2 Dose of Autologous T Cells Engineered With an Affinity-enhanced TCR Targeting NYESO1 and LAGE1a, and Co-expressing CD8ฮฑ (GSK3901961) in Participants With NYESO1 and/or LAGE1a Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma / Myxoid/Round Cell Liposarcoma; or NYESO1 and/or LAGE1a Positive Previously Treated Metastatic Non-Small Cell Lung Cancer

Study Focus

Neoplasms

GSK3901961

Interventional

drug

Sponsor & Location

GlaxoSmithKline

New Haven,Jacksonville,Tampa,Atlanta,Westwood,Lexington,Baltimore,Saint Louis,New York,New York,Philadelphia,Houston,Melbourne,Toronto,Montrรฉal,Muenchen,Hannover,Koeln,Dresden,Amsterdam,Stockholm, Australia,Canada,Germany,Netherlands,Sweden,United States of America

Timeline & Enrollment

Phase 1

Mar 09, 2021

May 26, 2023

7 participants

Primary Outcome

Number of Participants with Dose Limiting Toxicities (DLTs),Number of Participants with Adverse Events (AEs), Serious AEs and Adverse Events of Special Interest (AESI) based on Severity

Summary

The primary purpose of this sub study is to assess the safety, tolerability and determine
 recommended Phase 2 dose (RP2D) of GSK3901961 in HLA A*02:01, HLA-A*02:05 and/or HLA A*02:06
 positive participants with New York esophageal squamous cell carcinoma (NY ESO 1) and/or
 Cancer testis antigen 2 (LAGE 1a) positive previously treated metastatic Non-Small Cell Lung
 Cancer (NSCLC) and previously treated, advanced (metastatic or unresectable) Synovial
 Sarcoma/ Myxoid/Round Cell Liposarcoma SS/MRCLS.

ICD-10 Classifications

Neoplasms
In situ neoplasms
Personal history of other neoplasms
Benign neoplasms
Malignant neoplasms

Data Source

ClinicalTrials.gov

NCT06048705

Non-Device Trial